Please rotate your device

6 REASONS TO ADD THE PROPEL FAMILY OF IMPLANTS TO YOUR SINUS SURGERY ARMAMENTARIUM

Provides your sinus surgery patients with individualized treatment options1-3

  • Intersect ENT has a complete portfolio of implants indicated for use following ESS
  • Intersect ENT offers a family of 3 steroid-eluting implants under one brand: PROPEL
  • The PROPEL family of steroid-eluting implants provides you with the flexibility to treat different sinus anatomies, including the ethmoid, maxillary, and frontal sinuses in a multitude of patient types
  • PROPEL implants promote a tailored approach to postoperative care with options on implants’ indication, size, shape, and delivery system
  • The PROPEL implant provides localized delivery of mometasone furoate (MF), minimizing the reliance of patient compliance

ESS, endoscopic sinus surgery.

Breakthrough technology that opens the sinus cavity and delivers mometasone furoate1-3

  • PROPEL implants feature an innovative 2-in-1 mechanism that opens the sinuses while delivering mometasone furoate, an advanced corticosteroid, directly where it is needed
  • Mometasone furoate was selected for use in PROPEL implants for its optimal sinonasal drug characteristics: highly lipophilic, targeted and potent, and low systemic bioavailability
  • PROPEL implants are composed of a bioabsorbable polymer that breaks down between 30-45 days so implant removal is not required
  • PROPEL has a non-obstructive self-expanding design that allows for mucociliary clearance and the delivery of topical rinses

Delivers the power of robust, clinically proven benefits1-3

  • The efficacy and safety profiles were established in over 350 patients enrolled across 6 clinical studies
  • Proven in prospective randomized, blinded, intra-patient controlled trials to reduce

PROPEL

  • the need for postoperative interventions
  • the need for surgical interventions
  • the need for oral steroids
  • frank polyposis
  • significant adhesions
  • middle turbinate lateralization
  • patients’ perceived burden of symptoms

PROPEL Mini

  • the need for postoperative interventions
  • the need for surgical interventions
  • the need for oral steroids
  • occlusion/restenosis

PROPEL Contour

  • the need for postoperative interventions
  • the need for surgical interventions
  • occlusion/restenosis
  • inflammation
  • PROPEL in the ethmoid is proven to positively impact patients’ perceived burden of symptoms at 6 months

Proven success in the real world1-6

  • With more than 7 years of real-world use and over 300,000 patients treated, the trusted performance of PROPEL family of implants provide patients with proven improvements in sinus surgery outcomes
  • Supported by Level 1-A evidence to significantly improve outcomes of ethmoid sinus surgery
  • First and only FDA-approved steroid-eluting sinus implant
  • PMA-approved
  • 15+ peer-reviewed publications

Efficacious regardless of disease severity4

PROPEL demonstrated efficacy across multiple patient types:

  • With and without nasal polyps
  • Undergoing primary and revision surgery
  • Undergoing traditional and ballooning surgery

Intersect ENT partnership and collaboration

  • One of the only companies specifically dedicated to innovation in the field of otolaryngology
  • Dedicated to improving the quality of life for patients with ENT conditions providing robust clinical evidence
  • Continued collaboration with physicians to innovate and transform CRS care

CRS, chronic rhinosinusitis.

Complete your in-office
arsenal with PROPEL

Watch Dr. Matheny discuss the postoperative use of PROPEL in the office, following a bilateral ethmoidectomy in an ambulatory surgery center

HISTORY AND PRESENTING SYMPTOMS*

  • Long history of CRS without nasal polyps and allergic rhinitis

  • Maximally managed with daily allergy medication, immunotherapy, antibiotics (5-6 times per year), and oral steroids (3-4 times per year)

  • Continued to suffer from nasal obstruction, facial pain and pressure, periorbital headache, changes to taste and smell, and nasal drainage

  • Underwent total bilateral ethmoidectomy with concurrent balloon catheter dilation of the frontal and maxillary sinus outflow tracts, in an ambulatory surgery setting

  • In this ambulatory surgery setting, the patient did not have access to PROPEL

  • Next steps: Postoperative PROPEL placement in the office

*This case is intended for general medical education purposes only and is not a substitute for independent clinical medical judgment.
Response to treatment may vary from patient to patient.

PROPEL FITS WITHIN YOUR IN-OFFICE PRACTICE

Improve sinus surgery outcomes for your patients with CRS by offering PROPEL implants in your in-office practice through a two-pronged approach: in-office sinus procedures or postoperatively.

PROPEL
IN-OFFICE
IMPLANT
OPTIONS

1

IN-OFFICE SINUS PROCEDURES

Implants following in-office ESS such as balloon sinus dilation

2

POSTOPERATIVE UTILIZATION

Implants during the postoperative healing period after sinus surgery

  • CLINICAL APPLICATION

  • Intended for use following sinus surgery to maintain patency, thereby reducing the need for postoperative surgical intervention and use of oral steroids1-3
  • Separate mucosal tissues, provide stabilization of the middle turbinate, prevent obstruction by adhesions, and reduce edema/inflammation1-3
  • Innovative 2-in-1 technology that opens the sinuses while delivering mometasone furoate directly where it is needed1-3
  • COVERAGE

  • Positive coverage and access with commercial payors, such as UnitedHealthCare, Blue Cross Blue Shield FEP, and HCSC*†
  • Positive coverage and access with government payors, such as VA, TriCare, and select Medicare plans*†
  • Billing a CPT code for in-office use of PROPEL implants is applicable
  • VALUE TO YOUR PRACTICE

  • Easily loaded; fast and precise deployment
  • Innovative technology for your patients with CRS, with tools to facilitate patient outreach
  • Dedicated team to assist with payor coverage and reimbursement
  • Tailored care for your patients with PROPEL implants: Implants of varying sizes and shapes indicated to treat the frontal, maxillary, and ethmoid sinuses1-3

Actor portrayal with simulated endoscopy.

CPT, current procedural terminology; ESS, endoscopic sinus surgery; FEP, federal employee program; HSCS, Health Care Service Corporation; VA, Veterans Affairs.
*Coverage information as of September 2020
DISCLAIMER: This is not a guarantee of payment, coverage, or reimbursement. Individual payer plans may vary.

Arm yourself with PROPEL in the office

MORE THAN 7,000 PATIENTS TREATED IN THE OFFICE SINCE 20117

Choose from 3 steroid-eluting implants under one brand to select the best option that conforms to the anatomical needs of your patients.

Visit the reimbursement resources for more information on processing and payment for PROPEL sinus implants when used in facility or non-facility settings.

VIEW REIMBURSEMENT RESOURCES

ETHMOID SINUS

PROPEL MINI (NDC: 10599-0001-01)

PROPEL (NDC: 10599-0000-01)

FRONTAL SINUS OSTIA

PROPEL MINI (NDC: 10599-0001-01)

PROPEL CONTOUR (NDC: 10599-0002-01)

MAXILLARY SINUS OSTIA

PROPEL CONTOUR (NDC: 10599-0002-01)

PROPEL implants were evaluated in clinical trials that included patients with and without nasal polyps, undergoing primary or revision surgery by traditional instrumentation or ballooning procedures5

YOUR PATIENTS + PROPEL = IMPROVED OUTCOMES

GET PROPEL

Stay Informed

This site is intended for healthcare professionals in the United States

Stay Informed

References

  1. PROPEL [Instructions for Use]. Menlo Park, CA: Intersect ENT; 2013.
  2. ROPEL Mini [Instructions for Use]. Menlo Park, CA: Intersect ENT; 2016.
  3. PROPEL Contour [Instructions for Use]. Menlo Park, CA: Intersect ENT; 2016.
  4. Han JK, Marple BF, Smith TL, et al. Effect of steroid-releasing sinus implants on postoperative medical and surgical interventions: an efficacy meta-analysis. Int Forum Allergy Rhinol. 2012;2(4):271-279.
  5. Data on file, Intersect ENT, Inc. Calculated Patients – PROPEL Family. Q2 2019.
  6. Food and Drug Administration. Approval Order. https://www.accessdata.fda.gov/cdrh_docs/pdf10/P100044S018A.pdf. Accessed June 28, 2019.
  7. Data on file. Intersect ENT, Inc. Through Q3 2020.